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Abstract
Drug abuse is today a growing global problem. Often the consumers are not aware about the type
of substances they are using and the correlated risks. In recent years, new psychoactive sub-
stances (NPS) appeared in the illicit market. The presence of NPS, such as synthetic cathinones,
cannabinoids and phenethylamines, which are known to be pharmacologically and toxicologically
hazardous, has been frequently reported. The aim of this study was the development of a liquid
chromatography–high-resolution mass spectrometry (LC–HRMS) method for a broad screening of
NPS in plasma. Data acquisition was in MS/MS and full-scan modes and the method was validated
for 25 NPS belonging to different chemical classes. Quantitative results have been obtained for
these analytes with limits of quantification ranging from 0.03 to 0.4 ng/mL. The method was pro-
ven to be suitable for the screening of additional substances; to this aim, a post-run library match-
ing was conducted for every sample with an in-house database containing over 300 NPS and
known metabolites. The library may be constantly expanded with new drugs, in order to obtain a
broad screening of NPS in biological matrices.
Introduction
Drug abuse is today a growing global problem that affects every soci-
ety and people of all ages. Often the consumers are not aware of the
type of substances they are using and the correlated risks. In recent
years, new psychoactive substances (NPS) often sold as “legal-highs”
(1) (psychoactive compounds not included in the list of controlled
substances) appeared in the illicit market. These substances are new
molecules, natural or synthetic, which are sold in smart shops as
incense, bath salts or standard not for human use. The United
Nations and the European Union have repeatedly reported the pres-
ence of NPS, such as synthetic cathinones, cannabinoids and phe-
nethylamines, which has been shown to be pharmacologically and
toxicologically hazardous (2). The number of NPS, >450 according
to the last EMCDDA report (3), has already exceeded the total num-
ber of substances under international control.
Screening of drugs of abuse in biological matrices has been trad-
itionally performed with immunological methods that allow rapid
and cheap analysis. However, these methods may not be appropriate
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com 519
for the detection of the new molecules continuously appearing on the
illicit market (4). Alternative screening methods are based on chro-
matography coupled with mass spectrometry (MS); these techniques
are the most used in forensic medicine and toxicology for confirm-
ation purposes (5–7). Gas chromatography coupled with MS
(GCMS) has been the most used technique for general unknown
screening or for systematic toxicological analysis both in clinical and
forensic toxicology (8); however, the identification is based on
library spectra or reference standard and information on NPS is not
always readily available. Today, liquid chromatography coupled with
MS (LC–MS) is frequently used for the analysis of NPS and several
methods may be found in the literature (9); however, they are often
not efficient because the standards are not always available. Using
triple quadrupoles, ion traps or hybrids analyzers, several qualitative
LC–MS-MS strategies can be employed, that is, full-scan (10–12),
information-dependent acquisition (13–15) and targeted multi-
reaction monitoring (16, 17). High-resolution mass spectrometry
(HRMS) exceed the limits of low resolution analyzers through the
determination of psychoactive substances and their metabolites
with high mass accuracy (5, 9). Based on the exact masses of a
molecule and the isotopic pattern, the chemical formula of a com-
pound can be confirmed or even ascertained, with a low rate of
false positives. The study of the fragments may be an additional
tool for identification of unknown substances, especially using
data-independent acquisition strategies (18). Several authors have
developed methods for the screening of multiple NPS (19, 20)
mainly on biological matrices such as blood (21–25), urine (19,
20, 26–32) and hair (33) but in most cases, the screening is limited
to groups of related substances. A comprehensive method for screen-
ing and quantification is still required for NPS.
In this study, we developed a sensitive and quantitative method
for the determination of NPS in plasma including 16 cathinones
and 9 synthetic cannabinoids by LC–Q-Orbitrap HRMS in tar-
geted-MS/MS acquisition mode. Sample preparation is based on a
simple protein precipitation and the method was validated accord-
ing to SWGTOX guidelines. The method was then proven to be
suitable for the screening of substances not included within the 25
initially considered; to this aim, a parallel full-scan acquisition is
conducted for every sample, allowing a post-run processing. The
mass spectra obtained are then compared with an in-house library
built with TraceFinder Software containing over 300 NPS and
known metabolites; the library may be constantly expanded with
new drugs found, in order to obtain a broad screening of NPS in
biological matrices.
Materials and methods
Chemicals and materials
The available standards were separated into two groups; Set one
(SET1): methcathinone; methylone; ethylcathinone; 4-fluoromethcathi-
none (4-FMC); butylone; dimethylcathinone, 3,4-dimethylmetcathinone
(3,4 DMMC), 4-methoxymethcathinone (methedrone); buphedrone;
ethylone; 4-methylethcathinone (4-MEC); pentylone; pentedrone;
MDPV; 1-naphyrone; naphyrone; AM 694; JWH 251; JWH 203; JWH
016; JWH 007; JWH 081; JWH 122; JWH 019; JWH 210 (1mg/mL).
Set two (SET2) 2-fluoromethcathionone (2-FMC); 2,5-dimethoxy-
4-bromophenethylamine (2C-B); 2,5-dimethoxyphenethylamine
(2C-H); 2,5-dimethoxy-4-isopropylthiophenethylamine (2C-T-4);
2,5-dimethoxy-4-propylthiophenetylamine (2C-T-7); 2-methoxymeth-
cathinone (2MeOMC); para-fluorophenylpiperazine (4-FPP); 1-(4-
methoxyphenyl)-piperazine (4-MeOPP); α-Pyrrolidinopentiophenone
(α-PVP); diethylcathinone; mephedrone (4MMC); Methoxetamine;
AM 1220; JWH 018; JWH 018 2-hydroxyindole metabolite; JWH
018 N-(5-hydroxypentyl) metabolite; JWH 018 N-pentanoic acid
metabolite; JWH 073; JWH 081; JWH 081 N-(5-hydroxypentyl)
metabolite JWH 200; JWH 250; MAM 2201; MAM 2201 N-
pentanoic acid metabolite; (±)-JWH 018 N-(4-hydroxypentyl)
metabolite; UR-144; UR-144 N-(5-hydroxypentyl)metabolite; WIN
55; XLR 11; XLR 11 N-(4-hydroxypentyl) metabolite. Both SET1
and SET2 were purchased from Cayman Chemical (Ann Arbor, MI,
USA) and LGC standard (Sesto San Giovanni, Milan, Italy) at a con-
centration of 1 or 0.1mg/mL based on availability. Formic acid,
methanol, acetonitrile and water were acquired from Fisher Scientific
(Fair Lawn, NJ, USA). All solvents employed in the extraction were
ultra-performance liquid chromatography (UPLC) grade, and LC–
MS grade in the chromatographic system.
Extraction procedure
In a 2-mL Eppendorf tube, 250 µL of human plasma was mixed
with 750 µL of ACN/MeOH (80/20) and maintained at −20°C for
5min. The sample is then centrifuged at 4,000 × g, 4°C for 15min.
The supernatant is transferred into a second Eppendorf tube and
centrifuged at 12,000 × g, 4°C for 15min. Finally, 100 µL of the
supernatant are mixed with 100 µL of water and the mixture is
transferred into screw top autosampler vials prior to injection.
Preparation of standard stock solution
Stock solutions were obtained by diluting each standard in the proper
amount of methanol in order to obtain individual stock solutions at
0.01 and 0.001mg/mL. All the stock solutions were stored at −20°C.
Instrumentation
A Thermo Scientific Ultimate 3000 RSLC system coupled with a
Thermo Scientific Q Exactive Mass spectrometer (Thermo Fisher
Scientific, Bremen, Germany) was used for the analysis. The
Ultimate 3000 RSLC system consisted of a degasser, a tertiary load-
ing pump, a binary eluting pump, a column oven and an RS
autosampler.
Liquid chromatography
Chromatographic separation was achieved with a BetaBasic18 col-
umn, 150 × 2.1 mm (Thermo Scientific, Bremen, Germany) held at a
temperature of 40°C and a flow rate of 0.6 mL/min. Mobile phases
were 0.1% formic acid in water (Phase A) and 0.1% formic acid in
acetonitrile (Phase B). The gradient elution was as follows: the initial
composition (5% B) was increased from 5% to 50% B over 4.5 min,
from 50% to 100% over 0.5min, held at 100% for 2min and
returned to initial conditions over 1min. A 2-min equilibration fol-
lowed, yielding a total run time of 10min.
Mass spectrometry
Detection was performed using a Q Exactive mass spectrometer
equipped with a heated electrospray ionization source (HESI-II); ion-
ization was operated in positive mode. Source conditions were as fol-
lows: spray voltage 4 kV, heater temperature 425°C, capillary
temperature 400°C, S-lens RF level 50, sheath gas flow rate 30 and
auxiliary gas flow rate 15. The gas used for spray stabilization,
collision-induced dissociation experiments in the higher energy
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collision dissociation (HCD) cell, and as damping gas in the C-trap
was nitrogen. The instrument was calibrated both in positive and
negative modes everyday. The mass spectrometer acquired a targeted
MS/MS (the inclusion list consists of SET1 analytes) and a full scan
at a resolution of 70,000 (full width at half maximum at m/z 450);
scan range 50–550m/z. Automatic gain control (AGC) was 2e5 and
maximum injection time 100ms. In targeted MS/MS, precursor ions
are selected in the quadrupole with a 0.4m/z window and subse-
quently fragmented in the HCD cell (normalized collision energy
(NCE) was set to 35%). The mass spectrometer performs a scan of
all the fragment ions at a resolution of 70,000 as well; two specific
product ions are used for data analysis with a mass tolerance of
5 ppm. The selected precursor masses and fragments are reported in
Table I.
TraceFinder™ software was used for method development and
routine analysis during validation.
Method validation
Linearity, limits of detection (LODs), limits of quantification
(LOQs), selectivity, matrix effect, precision and accuracy were eval-
uated according to SWGTOX guidelines (34) for the analytes
included in SET1.
Linearity, LODs and LOQs
Calibration standards were prepared in water/methanol (50:50).
They were prepared at nine concentration levels (each point was
analyzed in five separate runs), from LOQ to 50 ng/mL (in detail,
calibrator samples concentration were 0.02–0.05–0.1–0.5–1–5–10–
25–50). LOD was estimated for each compound in blank plasma
samples as the smallest concentration that gave a signal to noise
ratio (S/N) of 3.
As recommended by the SWGTOX guidelines, LODs were
derived experimentally on the fragment ion with lowest S/N analyz-
ing blank plasma samples and blank plasma samples spiked with
decreasing amount of standard solution at appropriate concentra-
tion. LOQs were determined similarly as the lowest concentration of
a substance needed to give a S/N of 10. In addition, it was verified
that relative standard deviation (RSD%) and bias were within
±20% at the LOQs level.
For positive identification of an analyte, the two selected frag-
ments must be observed at the same retention time (Rt) as in the
quality control (QC) samples (only deviations within ±0.02min
were acceptable) and the quantifier/qualifier ratio were required to
be within 20% of those in QC samples.
Recovery and matrix effect
Six plasma samples were spiked with the proper amount of stand-
ard stock solution before and after the extraction to reach a con-
centration of LOQ and 50 ng/mL. Recovery was calculated
comparing the average peak area of the samples spiked before (A)
and after extraction (B). Accordingly, R (%) = A/B × 100. Matrix
effect was estimated by comparison of the calibration curves
obtained in blank plasma and in water/methanol (50:50) for each
compound. Matrix effect was obtained by (bm/bs), where bs repre-
sents the slope of the curve prepared in solvent and bm is the slope
of the curve in matrix.
Accuracy and precision
Accuracy and precision were estimated at three concentration levels
(LOQ, 5 and 50 ng/mL) in fortified plasma samples; QC samples
were prepared by adding 10 uL of a methanolic solution at a suit-
able concentration to 240 uL of blank plasma specimens; the con-
centrations of the compounds in the plasma samples were calculated
from freshly prepared calibration curves. Precision was calculated as
RSD (RSD% = SD/mean× 100). Precision was evaluated for each
analyte in three different days from the areas of six plasma samples
per day spiked before extraction. Accuracy was calculated from six
plasma samples fortified before extraction step; the concentration
corresponding the mean peak area (Cc) was calculated using the
equation of the calibration curve and was compared with the theor-
etical concentration (Ct). Accordingly A% = Cc/Ct × 100.
Selectivity
The presence of matrix interferences at the Rt of the considered ana-
lytes was observed in 10 blank samples.
Post-run screening analysis
A post-run processing of the full-scan data is performed by means of
TraceFinder software. The mass spectra are hence compared with an
in-house library. An additional MS/MS targeted scan of the precursor
ions found is performed on the positive samples in order to generate
fragmentation spectra and confirm the identity of the compounds.
Creation of a NPS mass spectra library
A mass spectra library including over 300 NPS and metabolites was
built and introduced into TraceFinder software for a post-run ana-
lysis of the acquired samples. For each analyte, the library contains
the elemental composition (molecular formula) and the theoretical
accurate mass as well as the mass of the fragments and the tr when-
ever possible.
Table I. LC–HRMS parameters and retention times (Rt) of the
analytes acquired in target-MS/MS mode
Analytes Rt Precursor ion Fragment-1 Fragment-2
Methcathinone 2.14 164.11 146.09625 131.07292
Methylone 2.25 208.10 190.08960 160.07550
Dimethylcathinone 2.26 178.12 133.06464 105.07040
4-FMC 2.35 182.10 164.08667 149.06319
Ethylcathinone 2.37 178.12 160.11169 132.08052
Ethylone 2.47 222.11 204.10153 174.09102
Methedrone 2.52 194.12 176.10669 161.08325
Buphedrone 2.58 178.12 160.11176 147.08012
Butylone 2.69 222.11 204.10153 191.06985
4-MEC 3.00 192.14 174.12746 159.10396
Pentedrone 3.11 192.14 174.12746 161.09575
Pentylone 3.18 236.13 218.11707 205.08548
3,4 DMMC 3.32 192.14 174.12746 159.10396
MDPV 3.48 276.16 205.08559 175.07507
1-Naphyrone 4.39 282.18 211.11140 169.06451
Naphyrone 4.54 282.18 211.11140 155.04886
AM 694 6.14 436.06 309.15189 230.92987
JWH 251 6.34 320.20 214.12234 188.14307
JWH 203 6.36 340.15 312.15051 214.12239
JWH 016 6.37 342.18 214.12215 155.04881
JWH 081 6.44 372.20 214.12218 185.05939
JWH 007 6.45 356.20 228.13777 155.04883
JWH 122 6.47 356.20 214.12238 169.06458
JWH 019 6.50 356.20 214.12238 155.04881
JWH 210 6.58 370.22 214.12242 183.08320
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If a reference standard was available, the library information
related to the analyte was collected by injecting standard solutions.
Exact masses of precursor ions for which a standard was not avail-
able were calculated using Xcalibur™ software; when possible the
theoretical exact masses of the most prominent fragments were also
added in the database, based on a comprehensive review of litera-
ture data and on the known fragmentation route of analogous
compounds.
The settings in TraceFinder program include a threshold override
of 10,000, with S/N equal to 5 and a mass tolerance of 5 ppm for
the molecular ion, while a threshold of 5,000 and a mass tolerance
of 5 ppm for the fragments.
Performance evaluation of the established spectra library
In order to evaluate the performance of the in-house library, 25 differ-
ent plasma samples were spiked with the analytes included in SET2 at
different concentrations down to 0.5 ng/mL. The samples were pro-
cessed following the presented method and analyzed. A post-run ana-
lysis was then conducted with TraceFinder software by library search.
Figure 1. Extracted ion currents of SET1 analytes obtained by targeted-MS/MS scan from a spiked plasma sample.
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Results and discussion
LC–MS/MS optimization
The targeted LC–HRMS method proposed for the determination
of cathinones and synthetic cannabinoids includes a total of 25
analytes (SET1). The chromatographic conditions were optimized
in order to obtain the best separation, particularly for the analytes
with the same exact mass (Figure 1), that cannot be discriminated
only by MS. Two columns, Thermo Scientific BetaBasic8 and
Kinetex PFP of different length (15 and 10 cm) and different par-
ticle sizes (5 and 2.6 µm, respectively), were tested. The Betabasic
column was chosen since it allowed to achieve a better separation.
Both methanol and acetonitrile were tested as organic mobile
phases but the latter was chosen because the noise within the
entire run was significantly lower. The addition of formic acid
resulted in a slight enhancement of the signal for all the analytes.
Figure 2. Recovery (A) and matrix effect (B) obtained in the different tested conditions.
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Initially, the sample was injected directly after the extraction pro-
cedure, but this resulted in a split of the chromatographic peaks,
especially for the most polar analytes such as cathinones. For this
reason, the sample was diluted 1:1 with water before the injection.
In these conditions, drugs belonging to different chemical classes
are included in a single chromatographic run; while the methods
found in the literature, except for the one proposed by Sundstrom
et al. (28), generally consider a single class of analytes or perform
two separate runs when cathinones and cannabinoids are investi-
gated in the same method (24, 33).
Spray voltage, gas temperature and flows, which must be the
same over the whole run, were properly tuned to the conditions given
in Section 2.4 by injecting all the analytes, in direct flow injection
analysis. In addition, the effect of AGC, resolution, maximum ion
time, scan range, NCE, LC flow rate, on the sensitivity as well as the
number of scans per chromatographic peak was thoroughly studied
and optimized to obtain an optimal sensitivity. The Q Exactive spec-
trometer gave the opportunity to perform various acquisition modes:
full-scan, target SIM and target MS/MS were tested in this study. We
decided to use targeted-MS/MS mode, with an inclusion list of
25 analytes (SET1), coupled with a full-scan mode for a broader
screening. Target SIM allowed to reach a sensitivity similar to target
MS/MS; however, to achieve the minimum requirement of identifica-
tion points according to EU Commission Decision 2002/657/EC
(35), in addition to the fulfillment of Rt criteria, at least a precursor
ion and a product ion must be included in the method.
Plasma extraction
Plasma is a complex matrix composed of 92% water and mineral
salts and 8% proteins; protein precipitation was selected as sample
preparation because it is not analyte specific and is then suitable for
untargeted screening; additionally, it requires a reduced sample
handling and is less expensive than other extraction techniques.
We firstly evaluated the influence of the amount of organic solv-
ent used on the extent of protein precipitation. To obtain an almost
complete precipitation, it would be appropriate to add a volume at
least twice the volume of the sample to process (36); it was then
decided to add the solvent in a ratio of 3:1.
Different extraction solvents or mixture were evaluated, that is,
methanol, acetonitrile and acetonitrile:methanol. Based on the
results shown in Figure 2A, the mixture 80:20 (v:v) was chosen. In
fact, similar recoveries were obtained with the three tested solvents:
however, using the solvent mixture, it was possible to obtain a lower
matrix effect (calculated as the ratio between the peak areas of the
reference samples in the matrix and the reference samples in solution
model) for all the tested analytes (Figure 2B). Similar results were
found by Vincenti et al. (37).
The developed extraction method allows to obtain good recover-
ies (>75%) for all the tested analytes despite the considerable differ-
ences of the chemical properties; cathinones, similar to amphetamines
are relatively hydrophilic, while synthetic cannabinoids are extremely
lipophilic. It is then likely that NPS not included within the tested
analytes are properly extracted with this method. By selecting an
appropriate mixture of solvent, it was additionally possible to obtain
a reduced matrix effect despite the nonspecifity of the method.
Validation
Identification and linearity
Detection of analytes was performed in targeted MS/MS; identifica-
tion is based on Rt, the exact mass of the precursor ion and two
diagnostic fragments, fulfilling the EU Commission Decision 2002/
657/EC confirmation criteria.
Calibration standards were prepared in water:methanol. QC
samples were prepared with blank plasma specimens; according to
SWGTOX guidelines (34), the use of matrix-matched calibrators is
not essential if the validation parameters are accomplished.
LODs and LOQs
LODs were derived experimentally, as recommended by the
SWGTOX guidelines and are listed in Table II. To ensure a correct
identification of the analytes even at LOD levels, the latter were
determined on the fragment with the smallest S/N. LOQs were cal-
culated similarly; for the lowest concentration of calibrator, it was
verified that a RSD within 20% could be routinely achieved and
that ion ratios between the quantifying and qualifier ion were within
±20% of that established by the calibration standards.
Matrix effect and selectivity
Accurate assessment of matrix effects is crucial for LC–MS based
bioanalytical methods both in confirmatory analysis and for screen-
ing purposes. The calculated values for matrix effect are reported in
Table III. The variability of matrix effect, evaluated on five different
plasma samples, was <15% for all the analytes.
At the Rt of the analytes, no interfering signals were recorded by
analyzing drug-free samples, showing that the developed method
provided an optimal selectivity for all the tested analytes.
Precision and accuracy
Accuracy and precision were measured at three concentration values
using fortified plasma samples and resulted always within the limits
of 15%, as shown in Table III.
Table II. Regression data, LODs, LOQs for selected analytes (SET1)
Analyte Equation R2 LOD
(ng/mL)
LOQ
(ng/mL)
Methcathinone Y = 3E+06X + 570,562 0.9956 0.07 0.2
Dimethy
lcathinone
Y = 4E+06X + 2E+06 0.9927 0.08 0.3
Methylone Y = 3E+06X + 2E+06 0.9921 0.02 0.2
Ethylcathinone Y = 2E+06X + 61,022 0.9974 0.08 0.4
4-FMC Y = 1E+06X + 107,749 0.996 0.08 0.3
Butylone Y = 5E+06X + 4E+06 0.9929 0.04 0.1
Methedrone Y = 2E+06X + 1E+06 0.9929 0.07 0.2
Buphedrone Y = 2E+06X + 1E+06 0.9962 0.07 0.3
Ethylone Y = 4E+06X +1E+06 0.9958 0.04 0.1
4-MEC Y = 3E+06X + 3E+06 0.9949 0.03 0.1
3,4 DMMC Y = 4E+06X + 705,141 0.998 0.07 0.2
Pentylone Y = 4E+06X + 2E+06 0.9958 0.02 0.1
Pentedrone Y = 3E+06X + 1E+06 0.9967 0.07 0.2
MDPV Y = 8E+06X + 4E+06 0.9947 0.008 0.05
1-Naphyrone Y = 5E+06X + 2E+06 0.9964 0.01 0.05
Naphyrone Y = 1E+07X + 1E+07 0.9924 0.005 0.02
AM 694 Y = 6E+06X – 1E+06 0.9981 0.06 0.1
JWH 251 Y = 2E+07X – 919,156 0.9975 0.008 0.03
JWH 203 Y = 4E+06X + 1E+06 0.9944 0.01 0.05
JWH 016 Y = 7E+06X + 2E+06 0.992 0.008 0.03
JWH 007 Y = 1E+07X + 7E+06 0.9928 0.007 0.03
JWH 081 Y = 9E+06X + 2E+06 0.9926 0.009 0.03
JWH 122 Y = 2E+07X + 1E+07 0.9962 0.01 0.04
JWH 210 Y = 1E+07X + 806,324 0.9969 0.03 0.1
JWH 019 Y = 2E+07X + 1E+07 0.9962 0.06 0.2
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Post-run screening and library matching
The method, developed for the 25 NPS, was further extended in
order to obtain a broad screening of NPS in plasma samples.
Together with the MS/MS acquisition, a full-scan survey is per-
formed, allowing later data re-interrogation to screen for unex-
pected compounds. The obtained mass spectra may be compared
with spectral libraries in order to identify NPS, potentially included
in the sample. Initially, mass-spectral identification is based on the
precursor (molecular) ion exact mass and isotopic pattern; the ions
that match with those in the library are then introduced in an inclu-
sion list and in a subsequent run, a targeted MS/MS scan is per-
formed to confirm their identity by comparing the generated
fragments to the ones included in the library.
To this aim, an in-house library containing over 300 NPS and
metabolites was built. The information included in the library are
precursor ion accurate masses, Rts (when available) and MS/MS
fragment ions. Rts were initially available only for the 25 substances
included in the quantitative method; for the other compounds in the
library, an intermediate Rt (4.5 min) with a ±310 s window was
listed. In this way, the whole chromatographic run is covered and
the software is able to identify substances even not knowing the
exact Rt. In these conditions, Rt was not considered as a significant
criterion in the library search strategy, anyhow it has been proved
that reliable results are obtained.
The library search strategy was verified using 25 different sam-
ples of plasma obtained from volunteers. As proof of concept, the
samples were separated into two aliquots, an aliquot was processed
as is while the other was spiked with both the drugs included in
SET1 and SET2; samples were prepared at five different concentra-
tions (40, 10, 5, 1 and 0.5 ng/mL) in five replicates. These samples
were then injected in the HPLC–HRMS system and acquired with
the previously described method; a library matching was performed
by using TraceFinder software.
Table III. Precision (expressed as RSD%), accuracy and matrix
effect data
Analytes Precision
(RSD%)
Accuracy (%) Matrix
effect (%)
LOQ 5 50 LOQ 5 50
Methcathinone 11 2 3 99 90 97 113
Dimethylcathinone 1 4 1 103 109 91 97
Methylone 6 2 4 94 105 97 112
Ethylcathinone 11 12 13 84 102 101 107
4-FMC 5 5 2 101 102 99 90
Butylone 2 1 4 94 105 97 90
Methedrone 2 1 1 94 104 102 98
Buphedrone 4 2 8 96 102 101 86
Ethylone 2 4 3 95 104 100 90
4-MEC 2 3 6 95 102 97 106
3,4 DMMC 13 4 7 104 109 98 101
Pentylone 2 1 3 101 105 99 98
Pentedrone 1 2 7 97 102 94 94
MDPV 3 1 4 89 104 100 97
1-Naphyrone 7 3 4 80 107 102 91
Naphyrone 2 2 3 94 102 104 84
AM 694 1 2 9 98 101 96 83
JWH 251 7 4 9 84 89 97 92
JWH 203 9 10 13 85 87 84 95
JWH 016 5 4 10 91 90 87 95
JWH 007 2 2 2 85 95 93 108
JWH 081 13 2 7 125 111 100 85
JWH 122 2 3 2 95 99 90 93
JWH 210 5 4 8 87 96 95 91
JWH 019 2 2 4 95 96 92 84
Precision and accuracy are listed at three concentration levels, LOQ, 5 and
50 ng/mL.
Table IV. LODs values of the post-run screening for both SET1 and
SET2 analytes
Analyte LOD (ng/mL)
Methcathinone 1
Methylone 1
Dimethylcathinone 1
4-FMC 1
Ethylcathinone 1
Ethylone 1
Methedrone 1
Buphedrone 1
Butylone 5
Pentedrone 1
4-MEC 1
Pentylone 1
3,4 DMMC 1
MDPV 1
1-Naphyrone 1
Naphyrone 1
AM 694 0.5
JWH 251 0.5
JWH 203 0.5
JWH 016 1
JWH 081 0.5
JWH 007 0.5
JWH 122 0.5
JWH 019 0.5
JWH 210 0.5
2-FMC 5
2C-B 5
2C-H 5
2C-T-4 5
2C-T-7 5
2MeOMC 1
4-FPP 5
4-MeOPP 5
α-PVP 1
Diethylcathinone 1
Mephedrone 1
Methoxetamine 1
AM 1220 0.5
JWH 018 0.5
JWH 018 2-hydroxyindole metabolite 0.5
JWH 018 N-(5-hydroxypentyl) metabolite 0.5
JWH 018 N-pentanoic acid metabolite 0.5
JWH 073 0.5
JWH 081 0.5
JWH 081 N-(5-hydroxypentyl) metabolite 0.5
JWH 200 0.5
JWH 250 0.5
MAM 2201 0.5
MAM 2201 N-pentanoic acid metabolite 0.5
(±)-JWH 018 N-(4-hydroxypentyl) metabolite 0.5
UR-144 0.5
UR-144 N-(5-hydroxypentyl)metabolite 0.5
WIN 55 0.5
XLR 11 0.5
XLR 11 N-(4-hydroxypentyl) metabolite 0.5
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Figure 3. Examples of positive identifications with Tracefinder™ software: (A) JWH 200 (B) mephedrone.
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The 25 drug-free aliquots were negative to all the substances
included in the library, showing no false positives caused by endogen-
ous plasma compounds. Instead, the other aliquots were positive to all
the included drugs, at least for the most concentrated samples. In
Table IV, we report the LODs values for the tested drugs; LOD was
considered as the lowest concentration of analyte that yields a positive
result on the library match.
An additional MS/MS targeted scan with an inclusion list of the
precursor ions found was performed on the positive sample in order
to generate fragmentation spectra and confirm the identity of the
compounds; Rt was also confirmed and thence was included in the
in-house library.
An example of a positive identification is given in Figure 3A, which
represents the identification process of JWH 200. In the upper part of
the figure, the first attempt of identification, based on the precursor
ion exact mass and the isotopic pattern, is represented; at this first
stage, the precursor ions masses recorded in full scan are compared
against the library entries. In this example, a peak at Rt 4.71 with a
mass of 385.1910 corresponds to JWH 200 entry; the exact mass
matches with a mass tolerance of 5 ppm while the isotopic pattern give
a score of 100%. To confirm the identity of the compound, the MS/
MS fragments are compared to the ones included in the library; for
this purpose, the sample was reanalyzed introducing the precursor
exact mass identified in a targeted-MS/MS inclusion list. The results
obtained are shown in the lower part of the figure; the product ion
spectra of the ion 385.1910 include the fragments 155.0487 and
114.0913, which correspond to the fragments of JWH 200.
In Figure 3B, mephedrone identification is reported: in this
example, four peaks corresponding to the exact mass 178.1226 are
found. In fact, this mass corresponds to dimethylcathinone, ethylcathi-
none, buphedrone and mephedrone that are structural isomers. At the
first stage of identification, based on exact mass and isotopic pattern,
the four peaks could not be discerned; with the additional MS/MS
experiment, the peak at 2.76min could be unambiguously identified
as mephedrone since the fragments 160.1117 and 145.0882 only
matches with this entry.
Very recently, similar NPS screening approaches were described
by Concheiro et al. (29) and Paul et al. (30). In the former study, the
data were acquired in full-scan and data-dependent MS2 mode with
a Q-exactive analyzer; the method includes the determination of
40 NPS stimulants in urine but, being a data-dependent acquisition
approach, additional NPS may easily be introduced in the mass-
spectrometric method: however, no synthetic cannabinoids are
included at this time. In the second study, the same approach was
used with a quadrupole-time of flight analyzer, a data-dependent
algorithm was combined with a preferred target list (not including
synthetic cannabinoids) in order to obtain data-dependent MS2
spectra for 49 target compounds and/or the most abundant untar-
geted precursor ions; this is a promising approach but the generation
of a high number of MS/MS data causes a decreased strength of the
signal that negatively influences LODs and LOQs.
In our study, we decided to perform a sensitive target MS/MS
quantification of target compounds coupled with a full-scan screen-
ing, and if necessary, a targeted-MS/MS scan for confirmation of the
positive findings. In this way, improved sensitivity is achieved, which
is particularly important to the detection of synthetic cannabinoids,
given that their median concentration in blood matrices (serum) is
generally below 1 ng/mL (38). Another possible approach would
have been a full scan coupled with all ion fragmentation, as reported
by Sunstrom et al. (28); this strategy apart from giving a lower sensi-
tivity may be susceptible to the interference effect of co-eluting
matrix components that create problems in unambiguously tracing
back an MS spectrum to its precursor ion.
Our approach combines a target method in MS/MS with a full-
scan acquisition for broad screening; the MS/MS method, used for
quantification may be expanded with every positive library match with
minimal method validation steps. Screening for unexpected drugs
and quantification of target compounds are then performed in as single
run. Precursor ion accurate mass and isotopic pattern were previously
shown to be powerful means of identification (39); however, to exclude
false positives, the additional experiment in MS/MS is essential.
Conclusions
This work reports a LC–HRMS method for the determination of
NPS in plasma, which is suitable both for a sensitive and quantitative
analysis of cathinones and synthetic cannabinoids in targeted-MS/MS
acquisition mode and for the screening of substances not included
within the first set; to this aim, a parallel full-scan acquisition is con-
ducted for every sample, allowing a reliable post-run processing.
Sample preparation is based on a simple protein precipitation and
the method was validated according to SWGTOX guidelines. For the
post-run screening, the mass spectra obtained is compared with an
in-house library containing over 300 NPS and known metabolites.
The opportunity to perform screening and confirmation in one
analytical run simplifies the workflow in forensic laboratories saving
time, costs and specimen volume. The presented approach provides
a very useful tool for the combined targeted analysis and broad
screening of drugs of abuse in plasma.
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